HSIC vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
HSIC exhibits strong fundamental health with a Piotroski F-Score of 7/9, indicating robust operational efficiency and financial stability. While the current price of $75.34 is well above the defensive Graham Number ($45.41), it trades at a discount to its growth-based intrinsic value of $89.60 and the analyst target of $89.23. The company shows positive YoY revenue and earnings growth, though thin profit margins and bearish insider sentiment provide a cautionary counterweight. Overall, the valuation appears attractive on a forward P/E basis (12.82) relative to its historical stability.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
HSIC vs LLY: Head-to-Head Comparison
This page compares Henry Schein, Inc. (HSIC) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.